MedTrace Logo

Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)

NCT03476070 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2021-09-05

No results posted yet for this study

Summary

This study aims to evaluate the prevalence, biological mechanism and survivorship impact of cognitive toxicity among adolescent and young adult (AYA) patients diagnosed with curable cancers. The hypothesis is that cognitive impairment is clinically significant among AYA cancer patients treated with chemotherapy and that there will be detectable structural and functional changes in the brain for this patient group.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Alexandre Chan, Pharm D · National University of Singapore, National Cancer Centre Singapore

Eligibility

Min Age
15 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-18
Primary Completion
2022-03-01
Completion
2022-09-01

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03476070 on ClinicalTrials.gov